Laucysteinamide A, a hybrid PKS/NRPS metabolite from a Saipan cyanobacterium, cf. Caldora penicillata

TitleLaucysteinamide A, a hybrid PKS/NRPS metabolite from a Saipan cyanobacterium, cf. Caldora penicillata
Publication TypeJournal Article
Year of Publication2017
AuthorsZhang C., Naman C.B, Engene N, Gerwick WH
JournalMarine Drugs
Volume15
Date Published2017/04
Type of ArticleArticle
ISBN Number1660-3397
Accession NumberWOS:000404228300037
Keywordsagents; blue-green alga; brine shrimp; cyanobacteria; Cytotoxicity; laucysteinamide A; lyngbya-majuscula; marine; molecular networking; natural-products; thiazoline alkaloid
Abstract

A bioactivity guided study of a cf. Caldora penicillata species, collected during a 2013 expedition to the Pacific island of Saipan, Northern Mariana Islands (a commonwealth of the USA), led to the isolation of a new thiazoline-containing alkaloid, laucysteinamide A (1). Laucysteinamide A is a new monomeric analogue of the marine cyanobacterial metabolite, somocystinamide A (2), a disulfide-bonded dimeric compound that was isolated previously from a Fijian marine cyanobacterium. The structure and absolute configuration of laucysteinamide A (1) was determined by a detailed analysis of its NMR, MS, and CD spectra. In addition, the highly bioactive lipid, curacin D (3), was also found to be present in this cyanobacterial extract. The latter compound was responsible for the potent cytotoxicity of this extract to H-460 human non-small cell lung cancer cells in vitro.

DOI10.3390/md15040121
Short TitleMar. Drugs
Student Publication: 
No
Research Topics: